Decoy Therapeutics Inc. SEC filings DCOY
Decoy Therapeutics Inc. has 743 filings in SEC EDGAR's recent list, going back to Aug 6, 2014. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 23, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Aug 4, 2026 | Sep 14, 2026 |
| DEFA14A | Additional proxy material | Aug 4, 2026 | — |
| PRE 14A | Preliminary proxy statement | Jul 24, 2026 | Jul 24, 2026 |
| DEFA14A | Additional proxy material | Jun 4, 2026 | — |
| DEF 14A | Proxy statement | Jun 4, 2026 | Jun 4, 2026 |
| DEF 14A | Proxy statement | Jan 9, 2026 | Feb 24, 2026 |
| PRE 14A | Preliminary proxy statement | Dec 29, 2025 | Feb 24, 2026 |
| DEFA14A | Additional proxy material | Dec 19, 2025 | — |
| DEFA14A | Additional proxy material | Nov 7, 2025 | — |
| DEF 14A | Proxy statement | Nov 7, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | May 27, 2025 | — |
| DEF 14A | Proxy statement | May 27, 2025 | May 27, 2025 |
| PRE 14A | Preliminary proxy statement | May 15, 2025 | May 15, 2025 |
| DEF 14A | Proxy statement | May 15, 2025 | May 15, 2025 |
| DEFA14A | Additional proxy material | Nov 1, 2024 | — |
| DEF 14A | Proxy statement | Nov 1, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Mar 26, 2024 | — |
| DEF 14A | Proxy statement | Mar 26, 2024 | Dec 31, 2023 |
| PRE 14A | Preliminary proxy statement | Mar 15, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEF 14A | Proxy statement | May 1, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | May 12, 2022 | — |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Dec 31, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2022 | Dec 31, 2021 |
| DEFA14A | Additional proxy material | Apr 27, 2021 | — |
| DEF 14A | Proxy statement | Apr 27, 2021 | Dec 31, 2020 |
| DEFA14A | Additional proxy material | Apr 29, 2020 | — |
| DEFA14A | Additional proxy material | Apr 29, 2020 | — |
| DEF 14A | Proxy statement | Apr 29, 2020 | Apr 28, 2020 |
| DEF 14A | Proxy statement | Sep 18, 2019 | Oct 21, 2019 |
| DEF 14A | Proxy statement | Apr 23, 2018 | Jun 6, 2018 |
| DEF 14A | Proxy statement | Apr 19, 2017 | Jun 1, 2017 |
| DEF 14A | Proxy statement | Apr 28, 2016 | Jun 7, 2016 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DCOY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1615219
- Former names
- Salarius Pharmaceuticals, Inc. (until Jan 9, 2026); Flex Pharma, Inc. (until Jul 22, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.